Aldeyra Therapeutics, Inc (NASDAQ:ALDX) CEO Buys $84,442.08 in Stock

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) CEO Todd C. Brady bought 14,288 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were acquired at an average price of $5.91 per share, with a total value of $84,442.08. Following the completion of the purchase, the chief executive officer now directly owns 614,826 shares of the company’s stock, valued at $3,633,621.66. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Todd C. Brady also recently made the following trade(s):

  • On Monday, September 9th, Todd C. Brady bought 10,000 shares of Aldeyra Therapeutics stock. The shares were acquired at an average price of $4.89 per share, with a total value of $48,900.00.

Shares of NASDAQ:ALDX opened at $5.92 on Monday. The company has a fifty day moving average of $5.12 and a 200-day moving average of $6.73. Aldeyra Therapeutics, Inc has a 52-week low of $4.31 and a 52-week high of $16.70.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.02. On average, sell-side analysts anticipate that Aldeyra Therapeutics, Inc will post -2.01 EPS for the current year.

Several equities research analysts have weighed in on ALDX shares. Zacks Investment Research cut Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 14th. Cantor Fitzgerald set a $33.00 target price on Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Finally, ValuEngine upgraded Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, September 10th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $26.79.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Aldeyra Therapeutics by 14.6% during the second quarter. BlackRock Inc. now owns 1,538,466 shares of the biotechnology company’s stock worth $9,231,000 after buying an additional 196,463 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Aldeyra Therapeutics by 4.0% during the second quarter. Vanguard Group Inc. now owns 1,111,944 shares of the biotechnology company’s stock worth $6,671,000 after buying an additional 42,869 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Aldeyra Therapeutics during the second quarter worth $1,950,000. Northern Trust Corp increased its holdings in shares of Aldeyra Therapeutics by 6.9% during the second quarter. Northern Trust Corp now owns 296,129 shares of the biotechnology company’s stock worth $1,777,000 after buying an additional 19,203 shares in the last quarter. Finally, Prescott Group Capital Management L.L.C. acquired a new position in shares of Aldeyra Therapeutics during the first quarter worth $948,000. Institutional investors own 61.26% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Further Reading: Purposes and Functions of the Federal Reserve

Insider Buying and Selling by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.